Table 1.
Concentration (ng/mL) of Anti-Pre-F IgG Binding Antibodies That Block 50% of Binding of Monoclonal Antibodies to Soluble DS-Cav1 Protein.
| Monoclonal Antibody | VLP Immunogen | ||
|---|---|---|---|
| Post-F | DS-Cav1 F | ||
| Am14 | Exp 1 | 950 +/− 70 | 65 +/− 5 |
| Exp 2 | 675 +/− 170 | 95 +/− 7 | |
| Exp 3 | 1500 +/− 100 | 138 +/− 56 | |
| D25 | Exp 1 | 7500 +/− 4000 | 550 +/− 50 |
| Exp 2 | 2333 +/− 577 | 425 +/− 50 | |
| Exp 3 | 8333 +/− 2100 | 505 +/− 130 | |
| Motavizamab | Exp 1 | 2000 +/− 100 | 825 +/− 25 |
| Exp 2 | 1000 +/− 50 | 1000 +/− 100 | |
Shown are concentrations (ng/mL) of anti-pre-F binding IgG in pooled sera obtained at four weeks after boost immunizations with DS-Cav1 F VLPs or Post-F VLPs that blocked binding of mAb AM14, D25, or Motavizumab to the soluble pre-F protein target (DS-Cav1). Results are the mean of at least three separate determinations, with standard deviations indicated. Each group in each experiment (Exp) contained five mice. Values at or somewhat above 2000 ng/mL indicate sera that only very weakly blocked binding. Values at or above 2000 ng/mL were quite variable from experiment to experiment, as indicated by the large standard deviation.